RTB 1
实时TB 1
基本信息
- 批准号:10886852
- 负责人:
- 金额:$ 8.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-01 至 2026-11-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAntibodiesAreaAutomobile DrivingBedsBiologicalCellsCellular AssayClinicalCollaborationsComplexCytometryDevelopmentDimensionsDiseaseDistant MetastasisEpitheliumEventFibroblastsFoundationsFrequenciesGene Expression ProfilingGoalsHumanImageImaging technologyImmuneInflammatoryInvadedLabelLiverMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMapsMesenchymalMolecularMolecular AnalysisMorphologyNeoplasm MetastasisPancreasPancreatic Ductal AdenocarcinomaPerformancePopulationPrimary NeoplasmProcessPrognosisProteomicsResearchResolutionSamplingStromal CellsStructureTechniquesTestingTissue ModelTissue SampleTissuesValidationVeinsVenousWorkcancer cellcancer imagingcell typedeep learningdimensional analysishigh dimensionalityhuman tissueimaging platformimprovedinsightmouse modelmulti-scale modelingmultiple omicsnew therapeutic targetnovelnovel strategiespancreatic cancer modelpancreatic ductal adenocarcinoma cellpancreatic neoplasmpancreatic tumorigenesispreventprogramsreconstructionsynergismtechnology developmenttooltranscriptometranscriptomicstumor microenvironment
项目摘要
Project Summary
Pancreatic cancer is a deadly disease with a dismal prognosis and a high frequency of distant metastasis. One
likely reason for the frequent metastases in pancreatic cancer is the ability of malignant cells in the primary tumor
to invade veins, providing direct access to the liver. While this intravasation is a key first step in metastasis, little
is known about the molecular and cellular alterations that underlie this process. Foci of cancer cell intravasation
are small and complex, requiring high-resolution three-dimensional (3D) approaches to study them. In this
Research Test Bed of our Center for 3D Multiscale Cancer Imaging, we will comprehensively characterize the
morphological, cellular, and molecular alterations of foci of intravasation in 3D in human pancreatic cancer
samples. In collaboration with Technology Development Unit 1, we will employ our novel deep learning 3D
reconstruction approach CODA to serially sectioned pancreatic cancer samples with venous invasion to quantify
morphological and cellular features of intravasation. We will also perform multi-dimensional immune profiling of
these intravasation foci in 3D using imaging mass cytometry, which can label with 40 antibodies on each tissue
section. These analyses will allow us to compare the tumor microenvironment in foci of intravasation to that in
other areas of cancer and in uninvolved veins. In collaboration with Technology Development Unit 2, we will
analyze the gene expression changes in these intravasation foci by applying a newly developed spatial
transcriptomics/proteomics approach (DBit-Seq) to pancreatic cancer samples previously reconstructed by
CODA. This approach will provide the first 3D multi-scale models of venous invasion in human pancreatic cancer,
providing unprecedented morphological, cellular, and molecular detail of the process of intravasation and
initiation of metastasis. In addition, our Research Test Bed will provide a critical opportunity to implement,
validate, and iteratively improve the novel approaches from the two Technology Development Centers. We will
work closely with these Technology Development Centers in order to evaluate the performance of CODA and
DBit-Seq in our human pancreatic tissue samples, allowing validation of the cell type identification and molecular
alterations by complementary techniques. The studies in our Research Test Bed will promote significant
improvement of the CODA and DBit-Seq imaging platforms while also providing important biological insights into
the initiation of metastasis in pancreatic cancer.
项目摘要
胰腺癌是一种预后差、易发生远处转移的致命疾病。一
胰腺癌频繁转移的可能原因是原发肿瘤中恶性细胞的能力
侵入静脉直接进入肝脏虽然这种内渗是转移的关键第一步,
是已知的分子和细胞的变化,这一过程的基础。癌细胞浸润灶
小而复杂,需要高分辨率的三维(3D)方法来研究它们。在这
我们的3D多尺度癌症成像中心的研究测试床,我们将全面表征
人胰腺癌血管内浸润灶的三维形态、细胞和分子改变
样品在与技术开发单位1的合作中,我们将采用我们新颖的深度学习3D技术,
重建方法CODA连续切片的胰腺癌样本与静脉浸润,以量化
内渗的形态学和细胞学特征。我们还将进行多维免疫分析,
使用成像质量细胞术在3D中观察这些血管内病灶,每个组织上可以标记40种抗体
科.这些分析将使我们能够比较肿瘤微环境的病灶内渗,
其他癌症区域和未受累静脉。我们会与技术发展组(二)合作,
应用新开发的空间分析技术分析这些血管内渗灶的基因表达变化
转录组学/蛋白质组学方法(DBit-Seq)对先前通过
结尾这种方法将提供人类胰腺癌静脉浸润的第一个3D多尺度模型,
提供了前所未有的形态学、细胞和分子细节的内渗过程,
转移的开始。此外,我们的研究试验台将提供一个实施的关键机会,
验证和迭代改进来自两个技术开发中心的新方法。我们将
与这些技术开发中心密切合作,以评估CODA的性能,
在我们的人类胰腺组织样本中使用DBit-Seq,可以验证细胞类型鉴定和分子生物学特性。
通过补充技术进行改造。在我们的研究试验床的研究将促进显着
CODA和DBit-Seq成像平台的改进,同时还提供了重要的生物学见解,
胰腺癌转移的起始。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Laura DeLong Wood其他文献
Laura DeLong Wood的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Laura DeLong Wood', 18)}}的其他基金
Characterization of the Molecular Determinants of High-Grade Dysplasia in Pancreatic Cancer Precursor Lesions
胰腺癌前驱病变高度不典型增生的分子决定因素的表征
- 批准号:
9751282 - 财政年份:2016
- 资助金额:
$ 8.19万 - 项目类别:
Characterization of the Molecular Determinants of High-Grade Dysplasia in Pancreatic Cancer Precursor Lesions
胰腺癌前驱病变高度不典型增生的分子决定因素的表征
- 批准号:
9321178 - 财政年份:2016
- 资助金额:
$ 8.19万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 8.19万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 8.19万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 8.19万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 8.19万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别: